Efficacy and Safety Study of Megafer injection® in Pregnant Wome
Phase 4
- Conditions
- Iron Deficiency anemia.Iron Deficiency anemia, unspecified
- Registration Number
- IRCT201611037978N4
- Lead Sponsor
- Surge Laboratories Pvt. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Inclusion Criteria: Pregnant Women in second or third trimester, Hb: = 8 g/dl and serum ferritin levels are below than normal
Exclusion Criteria
Patient allergic to iron preparation or any other ingredient of Injection megafer.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increase in Hb level after initiation of treatment, achievement of target haemoglobin. Timepoint: 2 & 4 weeks after first dose. Method of measurement: Haemoglobin testing.
- Secondary Outcome Measures
Name Time Method Reported adverse events related to drug only. Timepoint: At every follow up visit. Method of measurement: Patient monitoring & Follow up calls to patients.